IDiyas

For the Inventor, By the Inventor

Brookline, MA, United States of America

Min Lu

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 13.5

ph-index = 3

Forward Citations = 23(Granted Patents)


Company Filing History:

goldMedal13 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 2019-2025

where 'Filed Patents' based on already Granted Patents

13 patents (USPTO):
1. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),
2. 12240867 - Arginase inhibitors and methods of use (2025-03-04),
3. 12215116 - Arginase inhibitors and methods of use (2025-02-04),
4. 12065438 - Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors (2024-08-20),
5. 11702430 - Aza-benzothiophene compounds as STING agonists (2023-07-18),
6. 11685761 - Cyclic di-nucleotide compounds as sting agonists (2023-06-27),
7. 11274111 - Arginase inhibitors and methods of use (2022-03-15),
8. 10793557 - Sting agonist compounds (2020-10-06),
9. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),
10. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),
11. 10730849 - Benzo[b]thiophene compounds as STING agonists (2020-08-04),
12. 10703738 - Benzo[b]thiophene compounds as STING agonists (2020-07-07),
13. 10414747 - Benzo[b]thiophene compounds as sting agonists (2019-09-17),

Title: Inventor Spotlight: Min Lu

Introduction

Min Lu is a prominent inventor based in Brookline, MA, known for his significant contributions to the pharmaceutical industry. With a remarkable portfolio of 13 patents, Lu's work focuses on innovative solutions in the field of medicinal chemistry.

Latest Patents

Min Lu's latest inventions include novel 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives, designed as potent LRRK2 inhibitors. These compounds hold potential for treating diseases linked to LRRK2 kinase, particularly Parkinson's Disease. Alongside this, he has developed formulations of arginase inhibitors, which are valuable in addressing arginase-related diseases. The pharmaceutical compositions he has created not only benefit the treatment landscape but also highlight his expertise in drug development.

Career Highlights

Min Lu is currently associated with Merck Sharp & Dohme Corporation, a leading global pharmaceutical company. His work at Merck has been instrumental in advancing research in therapeutic areas of high unmet medical need. Throughout his career, Lu's innovations have garnered attention, enhancing the potential for more effective treatments in various diseases.

Collaborations

Throughout his career, Min Lu has collaborated with various talented individuals, including coworkers Jared N. Cumming and Benjamin Wesley Trotter. Together, they have worked on groundbreaking research that combines their expertise in medicinal chemistry, leading to the development of critical pharmaceutical compounds.

Conclusion

Min Lu's contributions to the field of pharmacology and his impressive patent portfolio underscore his importance as an inventor. His ongoing work may significantly impact the treatment and prevention of serious conditions such as Parkinson's Disease, showcasing the vital role of innovation in healthcare. As the pharmaceutical landscape continues to evolve, inventors like Min Lu will undoubtedly remain at the forefront of medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…